A new technique had been attempted to increase the field of radiofrequency ablation of expandable electrode needles in the treatment of hepatic neoplasms much larger than the routinely covered size of 5-7 cm according to the needle size overcoming the technical difficulties usually met with in the overlapping balls technique due to the hyperechoic focus that develops at the needle tip making reinsertion difficult and inaccurate. In this technique, two or three needles were inserted from the start into the mass with accurate estimation of the exact field of ablation of each needle trying to cover the whole extent of the mass before application of radiofrequency waves. 40 patients were included in the study, all presented with hepatic neoplastic mass lesion that range in size between 7 and 10 cm in its maximum diameter. All had a pretreatment helical (triphasic) CT study for accurate delineation of the whole extent and vascularity of the mass. Two needles were sufficient to cover the whole extent of the mass in 23 patients (57%) while in the remaining 17 patients (43%) three needles were necessary. The procedure was done under general anathesia and ultra sound guidance, patients tolerated procedure well with smooth recovery. No major complications. Follow up spiral (triphasic) CT was done 2 weeks after ablation revealed percentage of tumour necrosis of 90% or more in 30 patients (75%), 70-90% in 6 patients (15%) while in the remaining four patients (10%) the percentage was 50-70% necrosis. In conclusion this technique should be considered in the treatment of hepatic masses larger than the usual field of the needle. Results: The median value of GPC-3 in HCC, DC, CC was significantly higher than chronic hepatitis and control groups. No significant correlation found between AFP and GPC-3. AUROC of AFP was 0.85 & AUROC of GPC-3 was 0.84. The diagnostic Sensitivity of AFP (20 ng/ml) was 70% with PPV 53.8%. The specificity was 85% with NPV 91.9%. While the diagnostic Sensitivity of GPC-3 (2 ng/ml) was 100% with PPV 27%. The specificity was 42.2% with NPV 100%. Combined serial approach of AFP and GPC-3 improved the specificity to 87.5%. Conclusion:GPC-3 although it is a serological test for early detection of HCC, it showed limited specificity, where It is detected in different stages of chronic liver disease, as it is an oncofetal protein produced by regenerating liver cells. The diagnostic signature approach for simultaneous determination of AFP and GPC-3 may improve the prediction accuracy of HCC patients in those showing seronegativity to AFP.